Crestovo
Crestovo is a clinical-stage biopharmaceutical company founded in 2014 in Cambridge, MA, developing Full-Spectrum Microbiota therapeutics derived from the human gut microbiome for clinical applications. Its operational trajectory is intertwined with successor entity Finch Therapeutics, which is in wind-down/IP-realization mode after a Phase 3 failure and Nasdaq delisting.
- Company typePublic
- Founded2016
- HeadquartersCambridge, United States
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What Crestovo does
Crestovo is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Cambridge, Massachusetts, that develops Full-Spectrum Microbiota therapeutic products designed to harness the human gut microbiome. Its core platform is built on insights from human microbiota transplantation studies, with the goal of producing standardized, clinically deployable microbiome-based interventions. The company operates in the microbial transplantation therapeutic space, serving healthcare and clinical institutions as its primary downstream customer segment.
As a clinical-stage entity, Crestovo's business model centers on biopharmaceutical research and development rather than commercial product sales, with no approved products or disclosed revenue. The broader addressable market for microbial transplantation kits is projected to reach USD 891.8 million by 2035, supported by clinical adoption trends, technological innovation in diagnostics, and ongoing regulatory activity. However, no Crestovo-specific pricing, partnership, distribution, or commercialization details are available in the input.
Crestovo's operational trajectory is closely tied to that of the successor microbiome entity (Finch Therapeutics), which discontinued its Phase 3 CP101 trial for recurrent C. difficile in January 2023, delisted from Nasdaq and completed SEC deregistration in October 2024, and as of early 2025 is focused on realizing value from its IP estate rather than advancing clinical programs. A January 2025 CFO resignation further signals organizational contraction. Specific Crestovo-branded operating status, leadership, pipeline, and pipeline-stage information is not available in the provided data.
Crestovo firmographics
Firmographics- Name
- Crestovo
- Legal name
- Finch Therapeutics Group, Inc.
- Website
- https://crestovo.com
- Company type
- Public
- Founded year
- 2016
- Operating status
- Operating
- Short description
- Crestovo is a clinical-stage biopharmaceutical company founded in 2014 in Cambridge, MA, developing Full-Spectrum Microbiota therapeutics derived from the human gut microbiome for clinical applications. Its operational trajectory is intertwined with successor entity Finch Therapeutics, which is in wind-down/IP-realization mode after a Phase 3 failure and Nasdaq delisting.
- Ownership category
- akta.pro rank
Crestovo industry classification
Industry- Product category
- Microbiome Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Fecal Microbiota Transplantation (FMT) & Microbiota Restoration Products (HLAAAFAE)
- akta.pro secondary industry
- Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling) (HLAAAFAK)
Keywords
Where Crestovo is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Crestovo business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Crestovo product offering
Product offeringCore offering
Crestovo is a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiota, a therapeutic approach that harnesses the human gut microbiome for clinical applications. The company focuses on creating standardized, regulated microbial transplantation solutions using defined microbial consortia. Its pipeline targets therapeutic use of microbiota in clinical settings, addressing the need for standardized microbial transplantation kits within healthcare.
Differentiator
Problem solved
Functional benefit
Products and services
- Full-Spectrum Microbiota
Quantifiable outcome
- Market growth to USD 891.8 million by 2035
Companies that use Crestovo
Customer profileSegments1 record
Ideal customer profiles1 record
Crestovo technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Crestovo partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Expansion highlights3 records
Crestovo competitors and assessment
Company assessmentEmerging players
- MaaT Pharma: MaaT Pharma is a European clinical-stage microbiome therapeutics company developing standardized FMT-derived products for acute and chronic indications, including C. difficile and oncology support. Comparable platform model with narrower commercial reach.
- BiomX: BiomX develops engineered phage and microbiome-based therapeutics, focused on GI and skin indications. Adjacent modality in the broader microbiome therapeutics category.
- Second Genome: Second Genome is a clinical-stage microbiome drug discovery company engineering protein therapeutics and small molecules identified through microbiome research, partially comparable in platform approach and customer base.
- Evelo Biosciences: Evelo develops single-strain microbiome therapeutics for inflammatory and immunology indications, representing an adjacent but partially overlapping therapeutic-area peer in the microbiome modality.
Direct peers
- Rebiotix (Ferring Pharmaceuticals): Rebiotix developed Rebyota, an approved FMT-based product for recurrent C. difficile now commercialized by Ferring. It is the closest commercial-stage analog to Crestovo's full-spectrum microbiota approach.
- Seres Therapeutics: Seres was a leading microbiome therapeutics company (VOWST for recurrent C. difficile) targeting identical indications with defined consortia approaches. It represents the most direct competitive comparator to Crestovo's full-spectrum microbiota strategy.
- Vedanta Biosciences: Vedanta develops defined bacterial consortia for GI and infectious disease indications, including C. difficile. Same disease targets, same regulatory pathway, same customer base of clinical institutions and healthcare providers.
- Finch Therapeutics: Finch acquired Crestovo's assets and developed CP101, the rebranded Full-Spectrum Microbiota product. It is the most direct peer because the successor entity literally operates from Crestovo's clinical foundation.
Broad incumbents
- Assembly Biosciences: Assembly Bio has explored microbiome-based approaches alongside its core virology portfolio. Broad biotech with partial product overlap relevant to investors comparing alternative microbiome exposure.
Regional players
- 4D Pharma: 4D Pharma was a UK-based clinical-stage microbiome company developing single-strain and consortium Live Biotherapeutic Products for GI and oncology indications. Comparable platform, with primary geographic presence in Europe.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
Crestovo financial estimates
Financial estimateRevenue estimate
Valuation estimate
Crestovo leadership team
Management profileNumber of profiles
Profiles1 record
Crestovo funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Crestovo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Crestovo
What does Crestovo do?
Crestovo is a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiota, a therapeutic approach that harnesses the human gut microbiome for clinical applications. The company focuses on creating standardized, regulated microbial transplantation solutions using defined microbial consortia. Its pipeline targets therapeutic use of microbiota in clinical settings, addressing the need for standardized microbial transplantation kits within healthcare.
Is Crestovo a public or private company?
Crestovo is a public company. It is classified as venture growth investor backed and is currently operating.
When was Crestovo founded?
Crestovo was founded in 2016.
Where is Crestovo based?
Crestovo is headquartered in Cambridge, United States, in the North America region.
Who are Crestovo's main competitors?
Emerging players on record are MaaT Pharma, BiomX, Second Genome and Evelo Biosciences. Direct peers are Rebiotix (Ferring Pharmaceuticals), Seres Therapeutics, Vedanta Biosciences and Finch Therapeutics. Assembly Biosciences is listed as a broad incumbent. 4D Pharma is listed as a regional player.
Does Crestovo have an API?
No public API is recorded for Crestovo.
What industry is Crestovo in?
Crestovo's product category is Microbiome Therapeutics. Its primary akta.pro industry code is HLAAAFAE, Fecal Microbiota Transplantation (FMT) & Microbiota Restoration Products, with a secondary code of HLAAAFAK, Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling). Its NAICS code is 325414 and its SIC code is 8000.